AKLRD and Nordic Bioscience announce collaboration
AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.
The partnership will assess the effectiveness of APPA both in
relieving OA pain and in ...